ATE238794T1 - Verwendung von einem draflazin analog zur schmerzbehandlung - Google Patents

Verwendung von einem draflazin analog zur schmerzbehandlung

Info

Publication number
ATE238794T1
ATE238794T1 AT98934969T AT98934969T ATE238794T1 AT E238794 T1 ATE238794 T1 AT E238794T1 AT 98934969 T AT98934969 T AT 98934969T AT 98934969 T AT98934969 T AT 98934969T AT E238794 T1 ATE238794 T1 AT E238794T1
Authority
AT
Austria
Prior art keywords
phenyl
draflazine
analog
derivative
4alkyl
Prior art date
Application number
AT98934969T
Other languages
English (en)
Inventor
Theo Frans Meert
Belle Herman Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE238794T1 publication Critical patent/ATE238794T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT98934969T 1997-06-16 1998-06-09 Verwendung von einem draflazin analog zur schmerzbehandlung ATE238794T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97201813 1997-06-16
PCT/EP1998/003664 WO1998057643A1 (en) 1997-06-16 1998-06-09 Use of draflazine-analogues for treating pain

Publications (1)

Publication Number Publication Date
ATE238794T1 true ATE238794T1 (de) 2003-05-15

Family

ID=8228446

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98934969T ATE238794T1 (de) 1997-06-16 1998-06-09 Verwendung von einem draflazin analog zur schmerzbehandlung

Country Status (10)

Country Link
US (1) US6403589B1 (de)
EP (1) EP0999840B1 (de)
JP (1) JP2002504134A (de)
KR (1) KR20010013387A (de)
AT (1) ATE238794T1 (de)
AU (1) AU8438798A (de)
CA (1) CA2294011A1 (de)
DE (1) DE69814089T2 (de)
ES (1) ES2199447T3 (de)
WO (1) WO1998057643A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU784848B2 (en) * 1999-12-20 2006-07-06 Zalicus Pharmaceuticals Ltd. Partially saturated calcium channel blockers
CA2903031C (en) * 2002-09-05 2019-04-16 Arturo Angel Polyethylene glycol cleansers useful for removing irritating compounds from bodily surfaces
WO2004101593A1 (ja) * 2003-05-16 2004-11-25 Kissei Pharmaceutical Co., Ltd. 5’−修飾ヌクレオシド誘導体及びその医薬用途
ES2353399T3 (es) * 2005-04-01 2011-03-01 Neurogesx, Inc. Aceites de capsaicinoides y métodos para obtenerlos y usarlos.
WO2011000945A2 (en) 2009-07-03 2011-01-06 Nensius Research A/S Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns
WO2015197567A1 (en) 2014-06-26 2015-12-30 F. Hoffmann-La Roche Ag Indolin-2-one or pyrrolo-pyridin-2-one derivatives
EP3371169B1 (de) 2015-11-06 2019-07-17 H. Hoffnabb-La Roche Ag Indolin-2-on-derivate zur verwendung in der behandlung des zns und zugehöriger erkrankungen
DK3371168T3 (da) 2015-11-06 2020-08-03 Hoffmann La Roche Indolin-2-on-derivater

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2368280A1 (fr) * 1976-10-20 1978-05-19 Theramex Nouvelle composition therapeutique presentant une activite anti-agregante plaquettaire, et son procede de preparation
US4766125A (en) 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
FR2513118A1 (fr) * 1981-09-18 1983-03-25 Rocador Sa Composition pharmaceutique a base de dipyridamol et de sel d'aluminium de l'acide acetylsalicylique pour combattre l'agregation plaquettaire
NZ223847A (en) 1987-04-01 1989-12-21 Janssen Pharmaceutica Nv Substituted piperazine derivatives and pharmaceutical compositions
US5236908A (en) 1991-06-07 1993-08-17 Gensia Pharmaceuticals, Inc. Methods of treating injury to the central nervous system
IL108524A0 (en) 1993-02-03 1994-05-30 Gensia Inc Imidazodiazepine analogs

Also Published As

Publication number Publication date
WO1998057643A1 (en) 1998-12-23
AU8438798A (en) 1999-01-04
EP0999840A1 (de) 2000-05-17
JP2002504134A (ja) 2002-02-05
KR20010013387A (ko) 2001-02-26
EP0999840B1 (de) 2003-05-02
DE69814089T2 (de) 2004-02-19
ES2199447T3 (es) 2004-02-16
DE69814089D1 (de) 2003-06-05
CA2294011A1 (en) 1998-12-23
US6403589B1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
IL110031A0 (en) Phenyl heterocycles, their manufacture and pharmaceutical compositions containing them
EA199700135A1 (ru) Ингибиторы клеточной адгезии
BG106867A (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases
ATE538794T1 (de) Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
MY129772A (en) Crystal modification of a n-phenyl- 2 - pyrimidineamine derivative, processes for its manufacture and its use
MY131388A (en) Inhibitors of hiv protease useful for the treatment of aids.
BR9809185A (pt) Diidropiranos fundidos
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
IN2005KO00312A (de)
PT705100E (pt) Guanidinas substituidas terapeuticas
NO990662L (no) Trombin-inhibitorer
NO972391L (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
ATE238794T1 (de) Verwendung von einem draflazin analog zur schmerzbehandlung
EE03771B1 (et) Tetrahüdropüridoühendid, neid sisaldav ravim ja nende kasutamine
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
MXPA04005809A (es) Inhibidores de proteinas quinasas.
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
PL336897A1 (en) Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
ATE392213T1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
BR9611520A (pt) Composto hemo-reguladores.
BG105763A (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
RU93045696A (ru) Ингибиторы протеазы вируса иммунодефицита человека, полезные для лечения спида

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties